July 22 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III DESIGN IN NON-SMALL CELL LUNG CANCER
- IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH FDA ON PHASE III DESIGN IN NON-SMALL CELL LUNG CANCER
- IMMUTEP LTD: TACTI-004 REGISTRATIONAL TRIAL WILL ENROL ABOUT 750 PATIENTS REGARDLESS OF PD-L1 EXPRESSION
News: IMM Immutep Announces Successful Meeting With FDA On TACTI-004 Phase III Trial Design
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $341.2M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $134.7K | 574.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 556258 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 160283 | 34 |
View Market Depth
| Last trade - 12.29pm 11/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |